Phase I Trial of N-acetylcysteine Shows Promise for Retinitis Pigmentosa
A phase I clinical trial indicates that N-acetylcysteine may slow cone degeneration in patients with retinitis pigmentosa.
Company
Pharmaceutical intelligence for N-acetylcysteine with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.